Article · Wikipedia archive · Last revised Jul 23, 2026

Pemafibrate

Pemafibrate, sold under the brand name Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.

Last revised
Jul 23, 2026
Read time
≈ 1 min
Length
117 w
Citations
2
Source
Wikipedia ↗
Pemafibrate
Clinical data
Trade namesParmodia
Other namesK-13675
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (2R)-2-[3-({1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid
CAS Number
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30N2O6
Molar mass490.556 g·mol−1
3D model (JSmol)
  • CC[C@H](C(=O)O)Oc1cccc(c1)CN(CCCOc2ccc(cc2)OC)c3nc4ccccc4o3
  • InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
  • Key:ZHKNLJLMDFQVHJ-RUZDIDTESA-N

Pemafibrate, sold under the brand name Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.1

In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.2

References

References

  1. Yamashita S, Masuda D, Matsuzawa Y (January 2020). "Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases". Current Atherosclerosis Reports. 22 (1): 5. doi:10.1007/s11883-020-0823-5. PMC 6978439. PMID 31974794.
  2. Pemafibrate Archived 2018-02-05 at the Wayback Machine, pharmacodia.com